Ashley Rosko, MD

Closing out their discussion, the panel shares remaining unmet needs in the treatment of newly-diagnosed and relapsed multiple myeloma.

Naresh Bumma, MD, reviews how he selects between CAR T-cell therapy and bispecific agents for patients with refractory multiple myeloma.

Naresh Bumma, MD, details other bispecific agents on the horizon for relapsed multiple myeloma treatment.

Abdullah Khan, MBBS, explains the current data on bispecific T-cell engaging antibodies for the treatment of relapsed multiple myeloma.

Ashley Rosko, MD, presents the case of a 72-year-old woman with relapsed multiple myeloma for discussion.

April Logue, APRN-CNP, shares her perspective on selecting between doublet and triplet regimens for patients with transplant-ineligible newly-diagnosed multiple myeloma.

Naresh Bumma, MD, reviews updated data from the MAIA trial in transplant-ineligible newly-diagnosed multiple myeloma.

Ashley Rosko, MD, presents the case of a 79-year-old female with transplant-ineligible newly-diagnosed multiple myeloma.

Barry Hammer, PA-C, defines high-risk multiple myeloma and explains the treatment adjustments needed for newly-diagnosed patients.

For clinicians practicing in the community, constant communication and education from those in institutions may help to produce the best quality of care for patients with multiple myeloma.

Ashley E. Rosko, MD, specializes in multidisciplinary care for elderly patients with multiple myeloma, and how to make treatment most accessible to them.

At first relapse, novel therapies are offered to patients with multiple myeloma at The Ohio State University Comprehensive Cancer Center-The James.

Ashley E. Rosko, MD, highlights potential changes on the horizon to the standard of care in multiple myeloma therapy, and discussed the personalization of treatment based on transplant eligibility.

Naresh Bumma, MD, reviews data from the final analysis of the GRIFFIN trial investigating a quadruplet induction therapy regimen in newly-diagnosed multiple myeloma and discusses how patients are evaluated for transplant.

Ashley Rosko, MD, presents the case of a 57-year-old male with newly-diagnosed multiple myeloma for discussion.

In this peer-to-peer discussion two experts discuss the nuances and challenges of treating elderly patients with myeloma, and why therapies need to be tailored based on frailty status rather than age.